BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Immunology - Obstetrics - Pediatrics and Child Health - Public Health and Epidemiology

A Clinical Prediction Rule for Histological Chorioamnionitis in Preterm Newborns
Published: Friday, October 05, 2012
Author: Jasper V. Been et al.

by Jasper V. Been, Sizzle F. Vanterpool, Jasmijn D. E. de Rooij, G. Ingrid J. G. Rours, René F. Kornelisse, Martien C. J. M. van Dongen, Christel J. A. W. van Gool, Ronald R. de Krijger, Peter Andriessen, Luc J. I. Zimmermann, Boris W. Kramer

Background

Histological chorioamnionitis (HC) is an intrauterine inflammatory process highly associated with preterm birth and adverse neonatal outcome. HC is often clinically silent and diagnosed postnatally by placental histology. Earlier identification could facilitate treatment individualisation to improve outcome in preterm newborns.

Aim

Develop a clinical prediction rule at birth for HC and HC with fetal involvement (HCF) in preterm newborns.

Methods

Clinical data and placental pathology were obtained from singleton preterm newborns (gestational age =32.0 weeks) born at Erasmus UMC Rotterdam from 2001 to 2003 (derivation cohort; n?=?216) or Máxima MC Veldhoven from 2009 to 2010 (validation cohort; n?=?206). HC and HCF prediction rules were developed with preference for high sensitivity using clinical variables available at birth.

Results

HC and HCF were present in 39% and 24% in the derivation cohort and in 44% and 22% in the validation cohort, respectively. HC was predicted with 87% accuracy, yielding an area under ROC curve of 0.95 (95%CI?=?0.92–0.98), a positive predictive value of 80% (95%CI?=?74–84%), and a negative predictive value of 93% (95%CI?=?88–96%). Corresponding figures for HCF were: accuracy 83%, area under ROC curve 0.92 (95%CI?=?0.88–0.96), positive predictive value 59% (95%CI?=?52–62%), and negative predictive value 97% (95%CI?=?93–99%). External validation expectedly resulted in some loss of test performance, preferentially affecting positive predictive rather than negative predictive values.

Conclusion

Using a clinical prediction rule composed of clinical variables available at birth, HC and HCF could be predicted with good test characteristics in preterm newborns. Further studies should evaluate the clinical value of these rules to guide early treatment individualisation.

  More...